Publication: Pro: Can Biomarkers be Gold Standards in Alzheimer's Disease?
Loading...
Open/View Files
Date
2010
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Sperling, Reisa, and Keith Johnson. 2010. Pro: Can biomarkers be gold standards in Alzheimer's disease?. Alzheimer's Research & Therapy 2: 17.
Abstract
Recent advances in biomarkers for Alzheimer’s disease (AD) now allow the visualization of one of the hallmark pathologies of AD in vivo, and combination biomarker profiles can now approximate the diagnostic accuracy of autopsy in patients with dementia. Biomarkers are already employed in clinical trials in prodromal AD for both subject selection and in monitoring therapeutic response. Ultimately the greatest utility of biomarkers may be in the preclinical stages of AD, to identify and track progression of the disease prior to significant cognitive impairment, at the point when disease modifying therapies are likely to be most efficacious.
Description
Other Available Sources
Research Data
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service